{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:30:45Z","timestamp":1786681845051,"version":"build-2736575974"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Lung adenocarcinoma, which is most common in non-smokers and women, rarely presents with diffuse pulmonary nodules. Distinguishing monoclonal intrapulmonary metastases (IPM) from polyclonal multiple primary lung cancers (MPLC) is essential for treatment planning. Although next-generation sequencing (NGS) accurately determines clonal origin, it can be costly and time-consuming. We report a lung adenocarcinoma case with diffuse solid nodules in a 52-year-old non-smoking female. Empirical treatment with aumolertinib resulted in rapid, homogeneous regression of lesions within four weeks, supporting an IPM diagnosis. This uniform treatment response suggests a practical diagnostic indicator for monoclonal disease when NGS is unavailable, facilitating concurrent diagnosis and therapy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1894879","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:22:48Z","timestamp":1786681368000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Aumolertinib response as a diagnostic clue for intrapulmonary metastases"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People\u2019s Hospital)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People\u2019s Hospital)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1392969","article-title":"Diagnosis and management of multiple primary lung cancer","volume":"14","author":"Dong","year":"2024","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13705","article-title":"Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of Malignant pleural effusion","volume":"18","author":"Wang","year":"2024","journal-title":"Clin Respir J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.11.016","article-title":"Differentiating separate primary lung adenocarcinomas from intrapulmonary metastases with emphasis on pathological and molecular considerations: recommendations from the international association for the study of lung cancer pathology committee","volume":"20","author":"Chou","year":"2025","journal-title":"J\u00a0Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100047","article-title":"Genomic profiling with large-scale next-generation sequencing panels distinguishes separate primary lung adenocarcinomas from intrapulmonary metastases","volume":"36","author":"Yang","year":"2023","journal-title":"Mod Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1159\/000533892","article-title":"Synchronous primary lung cancers containing discrete driver mutations in a never-smoker: Case report","volume":"16","author":"Davis","year":"2023","journal-title":"Case Rep Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.847","article-title":"Clinical implications of EGFR-associated MAPK\/ERK pathway in multiple primary lung cancer","volume":"12","author":"Liang","year":"2022","journal-title":"Clin Transl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-312","article-title":"Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations","volume":"14","author":"Lu","year":"2022","journal-title":"J Thorac Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2026.101375","article-title":"A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy","volume":"64","author":"Fukui","year":"2026","journal-title":"Respir Invest"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:22:51Z","timestamp":1786681371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1894879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":9,"alternative-id":["10.3389\/fonc.2026.1894879"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1894879","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1894879"}}